As Pfizer-Wyeth Combine Eye Vaccines Business, Novartis, GSK, Sanofi-Aventis And Indian Companies Brace For The Challenge
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - These may be early days for Pfizer and Wyeth to analyze growth strategies of their vaccines business in emerging markets like India, but existing players like GlaxoSmithKline, Merck, Novartis and a host of home-grown companies like Panacea Biotec, Serum Institute and Shantha Biotech already seem well positioned to accelerate their growth in the quickly emerging vaccines market
You may also be interested in...
Bold Reforms Needed for India’s Vaccine Industry To Boom - McKinsey
Pushed by an expanded immunization program and a steady flow of new generation vaccines, India’s vaccine industry could grow to $1.65 billion if projected scenarios unfold.
As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot
Bharat Biotech's rotavirus development is a public-private initiative with partners including the Indian government, CDC and NIH.
As GSK, Merck Slash Rotavirus Vaccine Prices, Bharat Biotech Eyes Supplies At $1 Per Shot
Bharat Biotech's rotavirus development is a public-private initiative with partners including the Indian government, CDC and NIH.